NCT01482013View on ClinicalTrials.gov

Safety Study of HPP854 in Subjects With Mild Cognitive Impairment or a Diagnosis of Mild Alzheimer's Disease

PHASE1TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Mild Alzheimer's DiseaseMild Cognitive Impairment
Interventions
DRUG

HPP854

Oral, once a day for 28 days.

DRUG

Placebo

Oral, once a day for 28 days.

Trial Locations (3)

27265

High Point Clinical Trials Center, High Point

27710

Duke Clinical Research Unit, Durham

33169

Elite Research Institute, Miami

Sponsors
All Listed Sponsors
lead

High Point Pharmaceuticals, LLC.

INDUSTRY